NL9201440A - Triantennaire clusterglycosiden, hun bereiding en toepassing. - Google Patents

Triantennaire clusterglycosiden, hun bereiding en toepassing. Download PDF

Info

Publication number
NL9201440A
NL9201440A NL9201440A NL9201440A NL9201440A NL 9201440 A NL9201440 A NL 9201440A NL 9201440 A NL9201440 A NL 9201440A NL 9201440 A NL9201440 A NL 9201440A NL 9201440 A NL9201440 A NL 9201440A
Authority
NL
Netherlands
Prior art keywords
group
glycoside
formula
residue
compound
Prior art date
Application number
NL9201440A
Other languages
English (en)
Dutch (nl)
Original Assignee
Univ Leiden
Nl Hartstichting
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leiden, Nl Hartstichting filed Critical Univ Leiden
Priority to NL9201440A priority Critical patent/NL9201440A/nl
Priority to DK93921124T priority patent/DK0655070T3/da
Priority to AT93921124T priority patent/ATE168694T1/de
Priority to AU48355/93A priority patent/AU674160B2/en
Priority to PCT/NL1993/000169 priority patent/WO1994004545A1/en
Priority to ES93921124T priority patent/ES2122041T3/es
Priority to US08/382,022 priority patent/US5885968A/en
Priority to DE69319912T priority patent/DE69319912T2/de
Priority to JP6506123A priority patent/JPH08502726A/ja
Priority to EP93921124A priority patent/EP0655070B1/en
Publication of NL9201440A publication Critical patent/NL9201440A/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/08—Polyoxyalkylene derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
NL9201440A 1992-08-11 1992-08-11 Triantennaire clusterglycosiden, hun bereiding en toepassing. NL9201440A (nl)

Priority Applications (10)

Application Number Priority Date Filing Date Title
NL9201440A NL9201440A (nl) 1992-08-11 1992-08-11 Triantennaire clusterglycosiden, hun bereiding en toepassing.
DK93921124T DK0655070T3 (da) 1992-08-11 1993-08-11 Triantennære klusterglycosider, deres fremstilling og anvendelse
AT93921124T ATE168694T1 (de) 1992-08-11 1993-08-11 Triantennar cluster glykoside, ihre herstellung und verwendung
AU48355/93A AU674160B2 (en) 1992-08-11 1993-08-11 Triantennary cluster glycosides, their preparation and use
PCT/NL1993/000169 WO1994004545A1 (en) 1992-08-11 1993-08-11 Triantennary cluster glycosides, their preparation and use
ES93921124T ES2122041T3 (es) 1992-08-11 1993-08-11 Glicosidos triantenarios aglomerados, su preparacion y utilizacion.
US08/382,022 US5885968A (en) 1992-08-11 1993-08-11 Triantennary cluster glycosides, their preparation and use
DE69319912T DE69319912T2 (de) 1992-08-11 1993-08-11 Triantennar cluster glykoside, ihre herstellung und verwendung
JP6506123A JPH08502726A (ja) 1992-08-11 1993-08-11 ３分枝性クラスタグリコシドの調製およびその用途
EP93921124A EP0655070B1 (en) 1992-08-11 1993-08-11 Triantennary cluster glycosides, their preparation and use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL9201440A NL9201440A (nl) 1992-08-11 1992-08-11 Triantennaire clusterglycosiden, hun bereiding en toepassing.
NL9201440 1992-08-11

Publications (1)

Publication Number Publication Date
NL9201440A true NL9201440A (nl) 1994-03-01

Family

ID=19861173

Family Applications (1)

Application Number Title Priority Date Filing Date
NL9201440A NL9201440A (nl) 1992-08-11 1992-08-11 Triantennaire clusterglycosiden, hun bereiding en toepassing.

Country Status (10)

Country Link
US (1) US5885968A (es)
EP (1) EP0655070B1 (es)
JP (1) JPH08502726A (es)
AT (1) ATE168694T1 (es)
AU (1) AU674160B2 (es)
DE (1) DE69319912T2 (es)
DK (1) DK0655070T3 (es)
ES (1) ES2122041T3 (es)
NL (1) NL9201440A (es)
WO (1) WO1994004545A1 (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030386A1 (fr) * 1995-03-31 1996-10-03 Drug Delivery System Institute, Ltd. Derives d'amidite et derives d'oligonucleotides
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
DE19631189A1 (de) * 1996-08-02 1998-02-05 Max Delbrueck Centrum Neuartige kationische Amphiphile für den liposomalen Gentransfer
US6977244B2 (en) 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
GB2372502B (en) * 2000-12-12 2004-10-13 Imperial College Carbohydrate compounds containing cholesterol and their use
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP3023495B1 (en) 2010-02-24 2019-05-08 Arrowhead Pharmaceuticals, Inc. Compositions for targeted delivery of sirna
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
MX346144B (es) 2010-12-17 2017-03-09 Arrowhead Res Corp * Porcion activadora del modulador farmacocinetico del agregado de galactosa para arnsi.
US8932572B2 (en) 2011-08-26 2015-01-13 Arrowhead Madison Inc. Poly(vinyl ester) polymers for in vivo nucleic acid delivery
US20140100178A1 (en) * 2012-10-04 2014-04-10 Aslam Ansari Composition and methods for site-specific drug delivery to treat malaria and other liver diseases
CN104884618A (zh) 2012-11-15 2015-09-02 罗氏创新中心哥本哈根有限公司 寡核苷酸缀合物
CA2893801A1 (en) 2013-01-30 2014-08-07 F. Hoffmann-La Roche Ag Lna oligonucleotide carbohydrate conjugates
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
LT3013959T (lt) 2013-06-27 2020-03-10 Roche Innovation Center Copenhagen A/S Priešprasmiai oligomerai ir konjugatai, nukreirti į pcsk9
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
CA2979703A1 (en) 2015-03-17 2016-09-22 Arrowhead Pharmaceuticals, Inc. Compositions and methods for inhibiting gene expression of factor xii
CA2991639A1 (en) 2015-08-07 2017-02-16 Arrowhead Pharmaceuticals, Inc. Rnai therapy for hepatitis b virus infection
JOP20210043A1 (ar) 2015-10-01 2017-06-16 Arrowhead Pharmaceuticals Inc تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
UY37146A (es) * 2016-03-07 2017-09-29 Arrowhead Pharmaceuticals Inc Ligandos de direccionamiento para compuestos terapéuticos
KR102417646B1 (ko) 2016-03-14 2022-07-07 에프. 호프만-라 로슈 아게 Pd-l1 발현의 감소를 위한 올리고뉴클레오티드
EP3228326A1 (en) 2016-04-05 2017-10-11 Silence Therapeutics GmbH Nucleic acid linked to a trivalent glycoconjugate
MA45496A (fr) 2016-06-17 2019-04-24 Hoffmann La Roche Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
SG11201901841TA (en) 2016-09-02 2019-03-28 Arrowhead Pharmaceuticals Inc Targeting ligands
WO2018132432A1 (en) 2017-01-10 2018-07-19 Arrowhead Pharmaceuticals, Inc. Alpha-1 antitrypsin (aat) rnai agents, compositions including aat rnai agents, and methods of use
EP3483269A1 (en) 2017-11-13 2019-05-15 Silence Therapeutics GmbH Products and compositions
WO2018185253A1 (en) 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Ligand modified double-stranded nucleic acids
EP4029942A1 (en) 2017-04-05 2022-07-20 Silence Therapeutics GmbH Products and compositions
EP3385380A1 (en) 2017-04-05 2018-10-10 Silence Therapeutics GmbH Products and compositions
FI3607069T3 (fi) 2017-04-05 2023-01-13 Tuotteita ja koostumuksia
EP3550022A1 (en) 2018-04-05 2019-10-09 Silence Therapeutics GmbH Products and compositions
EP3385272A1 (en) 2017-04-05 2018-10-10 Silence Therapeutics GmbH Further novel oligonucleotide-ligand conjugates
CN110573619A (zh) 2017-04-05 2019-12-13 赛伦斯治疗有限责任公司 产品和组合物
EP3385381A1 (en) 2017-04-05 2018-10-10 Silence Therapeutics GmbH Products and compositions
WO2018185252A1 (en) 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Nucleic acid conjugates
JOP20200054A1 (ar) 2017-09-11 2020-03-10 Arrowhead Pharmaceuticals Inc عوامل RNAi وتركيبات لتثبيط تعبير صَميمُ البروتينِ الشَّحْمِيّ C-III (APOC3)
EP3681513A4 (en) 2017-09-14 2021-09-22 Arrowhead Pharmaceuticals, Inc. RNAI AGENTS AND COMPOSITIONS FOR INHIBITING THE EXPRESSION OF ANGIOPOIETIN-LIKE 3 (ANGPTL3) AND METHOD OF USE
KR102585898B1 (ko) 2017-10-16 2023-10-10 에프. 호프만-라 로슈 아게 B형 간염 감염을 치료하기 위한 PAPD5 및 PAPD7 mRNA의 감소용 핵산 분자
US11492624B2 (en) 2017-10-17 2022-11-08 Arrowheads Pharmaceuticals, Inc. RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1
CA3118327A1 (en) 2017-11-13 2019-05-16 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of aldh2 in a cell
EP3710586B1 (en) 2017-11-13 2022-11-23 Silence Therapeutics GmbH Nucleic acids for inhibiting expression of lpa in a cell
EP3483270A1 (en) 2017-11-13 2019-05-15 Silence Therapeutics GmbH Products and compositions
EP3710585A1 (en) 2017-11-13 2020-09-23 Silence Therapeutics GmbH Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages
EP3775207A1 (en) 2018-04-05 2021-02-17 Silence Therapeutics GmbH Sirnas with vinylphosphonate at the 5' end of the antisense strand
EP3550021A1 (en) 2018-04-05 2019-10-09 Silence Therapeutics GmbH Products and compositions for inhibiting expression of a target gene
CN112567033A (zh) 2018-07-03 2021-03-26 豪夫迈·罗氏有限公司 用于调节Tau表达之寡核苷酸
EP3598995A1 (en) 2018-07-26 2020-01-29 Silence Therapeutics GmbH Products and compositions
EP3844274A1 (en) 2018-08-28 2021-07-07 Roche Innovation Center Copenhagen A/S Neoantigen engineering using splice modulating compounds
HUE060703T2 (hu) 2018-11-13 2023-04-28 Silence Therapeutics Gmbh Nukleinsavak LPA expressziójának gátlására egy sejtben
EP3730617A1 (en) 2019-04-26 2020-10-28 Silence Therapeutics GmbH Nucleic acids for inhibiting expression of c3 in a cell
CA3119234A1 (en) 2018-11-23 2020-05-28 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of c3 in a cell
WO2020163747A1 (en) 2019-02-07 2020-08-13 Arrowhead Pharmaceuticals, Inc. Rnai agents for hepatitis b virus infection
CN113474633A (zh) 2019-02-26 2021-10-01 罗氏创新中心哥本哈根有限公司 寡核苷酸配制方法
CA3135958A1 (en) 2019-05-07 2020-11-12 Universitat Bern Nucleic acids for inhibiting expression of pros1 in a cell
CA3141762A1 (en) 2019-06-06 2020-12-10 Arrowhead Pharmaceuticals, Inc. Methods for the treatment of alpha-1 antitrypsin deficiency (aatd)
CN114340664A (zh) 2019-06-18 2022-04-12 爱尔兰詹森科学公司 乙型肝炎病毒(HBV)疫苗和靶向HBV的RNAi的组合
CA3149534A1 (en) 2019-08-27 2021-03-04 Verena AUMILLER Nucleic acids for inhibiting expression of c3 in a cell
EP4081639A1 (en) 2019-12-24 2022-11-02 F. Hoffmann-La Roche AG Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
CN114828852A (zh) 2019-12-24 2022-07-29 豪夫迈·罗氏有限公司 用于治疗hbv的靶向hbv的抗病毒药剂和/或免疫调节剂的药物组合
KR20220158011A (ko) 2020-03-26 2022-11-29 애로우헤드 파마슈티컬스 인코포레이티드 PNPLA3의 발현을 억제하기 위한 RNAi 작용제, 이의 약제학적 조성물, 및 사용 방법
CA3184050A1 (en) 2020-05-27 2021-12-02 ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS-CIC bioGUNE Nucleic acids for inhibiting expression of cnnm4 in a cell
WO2022060721A2 (en) 2020-09-15 2022-03-24 Arrowhead Pharmaceuticals, Inc. Methods for the reduction of z-aat protein levels
TW202237840A (zh) 2020-11-04 2022-10-01 瑞士伯恩大學 用於在細胞中抑制pros1之表現的核酸
WO2022184852A1 (en) 2021-03-03 2022-09-09 Silence Therapeutics Gmbh Conjugated nucleic acids comprising a phosphorodithioate for inhibiting gene expression in a cell
WO2022223557A1 (en) 2021-04-20 2022-10-27 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of xdh in a cell
EP4329876A1 (en) 2021-04-27 2024-03-06 Silence Therapeutics GmbH Sirna targeting tmprss6 for the treatment of myeloproliferative disorders
US11549112B1 (en) 2021-06-21 2023-01-10 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
WO2023031359A1 (en) 2021-09-02 2023-03-09 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of complement factor b (cfb) in a cell
WO2023233290A1 (en) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Rnai agents targeting pd-l1
WO2024126687A1 (en) 2022-12-16 2024-06-20 Silence Therapeutics Gmbh Nucleic acids conjugated to an albumin binding moiety

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US751219A (en) * 1904-02-02 Leaf-turner
US4751219A (en) * 1985-02-05 1988-06-14 Nederlandse Centrale Organisatie Voor Toegepast-Natuur-Wetenschappelijk Onderzoek Synthetic glycolipides, a process for the preparation thereof and several uses for these synthetic glycolipides
FR2637185A1 (fr) * 1988-10-05 1990-04-06 Ire Celltarg Sa Vecteurs synthetiques de faible poids moleculaire, utilisation en therapie ciblee et en imagerie medicale et procedes de preparation
ATE190619T1 (de) * 1993-09-01 2000-04-15 Akzo Nobel Nv Biskonjugate, die zwei saccharide und einen spacer enthalten

Also Published As

Publication number Publication date
DE69319912D1 (de) 1998-08-27
DE69319912T2 (de) 1999-04-15
EP0655070A1 (en) 1995-05-31
DK0655070T3 (da) 1999-04-26
WO1994004545A1 (en) 1994-03-03
ATE168694T1 (de) 1998-08-15
AU4835593A (en) 1994-03-15
ES2122041T3 (es) 1998-12-16
AU674160B2 (en) 1996-12-12
EP0655070B1 (en) 1998-07-22
US5885968A (en) 1999-03-23
JPH08502726A (ja) 1996-03-26

Similar Documents

Publication Publication Date Title
NL9201440A (nl) Triantennaire clusterglycosiden, hun bereiding en toepassing.
AU681010B2 (en) Substituted lactose derivatives as cell adhesion inhibitors
EP0811011B1 (en) Carbohydrate conjugated bio-active compounds
US5354853A (en) Phospholipid-saccharide conjugates
HUT74506A (en) Sialyl lewis-x analogues as inhibitors of cellular adhesion
JPH10507742A (ja) シアル酸／フコースベースの医薬
US20050187171A1 (en) Glycomimetic antagonists for both E-and P-selectins
CA2160100A1 (en) Carbohydrate conjugates as inhibitors of cell adhesion
EP1763533B1 (en) Specific antagonist for both e- and p-selectins
AU678373B2 (en) Substituted lactose derivatives as cell adhesion inhibitors
AU595987B2 (en) Disaccharide derivatives
JP2535048B2 (ja) 新規ジサッカライド誘導体及びその塩
EP1549658B1 (en) Glucose-based compounds with affinity to p-selectin
JP2774429B2 (ja) 糖骨格を有する分枝鎖型誘導体
WO1999010359A2 (en) Liposomic based sialyl lewis x mimetics
JP2951975B2 (ja) 抗腫瘍剤
JPH06199884A (ja) 新規糖脂質誘導体
WO1998055149A1 (fr) Utilisation de vecteurs medicamenteux pour produire des medicaments migrants dans les ganglions lymphatiques
WO1991008748A1 (en) Synthesis of rotavirus receptor saccharides
IKAMI et al. Synthetic studies on sialoglycoconjugares. Part CVII. Synthetic Studies on Selectin Ligands/Inhibitors. Synthesis and Biological Evaluation of Sulfated and Phosphorylated. BETA.-D-Galacto-and Lactopyranosides Containing Fatty-Alkyl Residues of Different Carbon Chain Lengths.
JPH10152498A (ja) 糖脂質誘導体、それを有効成分とする免疫抑制剤およびその製造用中間体
Wright Synthesis of glycoconjugates affecting cell adhesion

Legal Events

Date Code Title Description
A1B A search report has been drawn up
BV The patent application has lapsed